# Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

> **NCT00748046** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 10 (actual)

## Conditions studied

- Prostate Cancer
- Metastases
- Pharmacokinetics

## Interventions

- **DRUG:** Radium-223 chloride (BAY88-8223)

## Key facts

- **NCT ID:** NCT00748046
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748046, "Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00748046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*